Literature DB >> 33894018

Differential abnormalities of cerebrospinal fluid dopaminergic versus noradrenergic indices in synucleinopathies.

David S Goldstein1, Patti Sullivan1, Courtney Holmes1, Guillaume Lamotte1, Abhishek Lenka1, Yehonatan Sharabi1.   

Abstract

The synucleinopathies Parkinson's disease (PD), multiple system atrophy (MSA), and pure autonomic failure (PAF) are characterized by intra-cytoplasmic deposition of the protein alpha-synuclein and by catecholamine depletion. PAF, which manifests with neurogenic orthostatic hypotension (nOH) and no motor signs of central neurodegeneration, can evolve into PD+nOH. The cerebrospinal fluid (CSF) levels of catecholamine metabolites may indicate central catecholamine deficiency in these synucleinopathies, but the literature is inconsistent and incomplete. In this retrospective cohort study we reviewed data about CSF catecholamines, the dopamine metabolites 3,4-dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA), and the norepinephrine metabolites 3,4-dihydroxyphenylglycol (DHPG) and 3-methoxy-4-hydroxyphenylglycol (MHPG). The compounds were measured in 36 patients with PD, 37 patients with MSA, and 19 patients with PAF and in 38 controls. Compared to the control group, the PD, MSA, and PAF groups had decreased CSF MHPG (p < .0001 each by Dunnett's post hoc test), DHPG (p = .004; p < .0001; p < .0001) and norepinephrine (p = .017; p = .0003; p = .044). CSF HVA and DOPAC were decreased in PD (p < .0001 each) and MSA (p < .0001 each) but not in PAF. The three synucleinopathies therefore have in common in vivo evidence of central noradrenergic deficiency but differ in the extents of central dopaminergic deficiency-prominent in PD and MSA, less apparent in PAF. Data from putamen 18 F-DOPA and cardiac 18 F-dopamine neuroimaging in the same patients, post-mortem tissue catecholamines in largely separate cohorts, and review of the neuropathology literature fit with these distinctions. The results suggest a 'norepinephrine first' ascending pathogenetic sequence in synucleinopathies, with degeneration of pontine locus ceruleus noradrenergic neurons preceding the loss of midbrain substantia nigra dopaminergic neurons.
© 2021 The Authors. This article is a U.S.Government work and is in the public domain in the USA.

Entities:  

Keywords:  HVA; MHPG; Parkinson; multiple system atrophy; norepinephrine; pure autonomic failure

Mesh:

Substances:

Year:  2021        PMID: 33894018      PMCID: PMC8529535          DOI: 10.1111/jnc.15371

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.546


  65 in total

1.  Levels of HVA, 5-HIAA, and MHPG in the CSF of vascular parkinsonism compared to Parkinson's disease and controls.

Authors:  Megan K Herbert; H Bea Kuiperij; Bastiaan R Bloem; Marcel M Verbeek
Journal:  J Neurol       Date:  2013-12       Impact factor: 4.849

2.  Cerebrospinal fluid levels of catecholamines and its metabolites in Parkinson's disease: effect of l-DOPA treatment and changes in levodopa-induced dyskinesia.

Authors:  Andreas Dammann Andersen; Morten Blaabjerg; Michael Binzer; Akram Kamal; Helle Thagesen; Troels Wesenberg Kjaer; Egon Stenager; Jan Bert Paul Gramsbergen
Journal:  J Neurochem       Date:  2017-03-30       Impact factor: 5.372

3.  Noradrenergic Activity in the Human Brain: A Mechanism Supporting the Defense Against Hypoglycemia.

Authors:  Renata Belfort-DeAguiar; Jean-Dominique Gallezot; Janice J Hwang; Ahmed Elshafie; Catherine W Yeckel; Owen Chan; Richard E Carson; Yu-Shin Ding; Robert S Sherwin
Journal:  J Clin Endocrinol Metab       Date:  2018-06-01       Impact factor: 5.958

4.  Defective autonomic control of blood vessels in idiopathic orthostatic hypotension.

Authors:  R Bannister; L Ardill; P Fentem
Journal:  Brain       Date:  1967-12       Impact factor: 13.501

5.  Cerebrospinal fluid biomarkers of central catecholamine deficiency in Parkinson's disease and other synucleinopathies.

Authors:  David S Goldstein; Courtney Holmes; Yehonatan Sharabi
Journal:  Brain       Date:  2012-03-26       Impact factor: 13.501

6.  Association of posttraumatic stress disorder with reduced in vivo norepinephrine transporter availability in the locus coeruleus.

Authors:  Robert H Pietrzak; Jean-Dominique Gallezot; Yu-Shin Ding; Shannan Henry; Marc N Potenza; Steven M Southwick; John H Krystal; Richard E Carson; Alexander Neumeister
Journal:  JAMA Psychiatry       Date:  2013-11       Impact factor: 21.596

7.  Parkinson's disease and dementia: norepinephrine and dopamine in locus ceruleus.

Authors:  R Cash; T Dennis; R L'Heureux; R Raisman; F Javoy-Agid; B Scatton
Journal:  Neurology       Date:  1987-01       Impact factor: 9.910

8.  Brain-first versus body-first Parkinson's disease: a multimodal imaging case-control study.

Authors:  Jacob Horsager; Katrine B Andersen; Karoline Knudsen; Casper Skjærbæk; Tatyana D Fedorova; Niels Okkels; Eva Schaeffer; Sarah K Bonkat; Jacob Geday; Marit Otto; Michael Sommerauer; Erik H Danielsen; Einar Bech; Jonas Kraft; Ole L Munk; Sandra D Hansen; Nicola Pavese; Robert Göder; David J Brooks; Daniela Berg; Per Borghammer
Journal:  Brain       Date:  2020-10-01       Impact factor: 13.501

Review 9.  Pure progressive autonomic failure: a clinicopathological study.

Authors:  Y Terao; K Takeda; M Sakuta; T Nemoto; T Takemura; M Kawai
Journal:  Eur Neurol       Date:  1993       Impact factor: 1.710

10.  6-[18F]fluoro-L-dopa metabolism in living human brain: a comparison of six analytical methods.

Authors:  H Hoshi; H Kuwabara; G Léger; P Cumming; M Guttman; A Gjedde
Journal:  J Cereb Blood Flow Metab       Date:  1993-01       Impact factor: 6.200

View more
  3 in total

Review 1.  Advances in Proteomic and Metabolomic Profiling of Neurodegenerative Diseases.

Authors:  Artur Schumacher-Schuh; Andrei Bieger; Wyllians V Borelli; Makayla K Portley; Paula Saffie Awad; Sara Bandres-Ciga
Journal:  Front Neurol       Date:  2022-01-31       Impact factor: 4.003

Review 2.  Cerebrospinal Fluid Metabolome in Parkinson's Disease and Multiple System Atrophy.

Authors:  Do Hyeon Kwon; Ji Su Hwang; Seok Gi Kim; Yong Eun Jang; Tae Hwan Shin; Gwang Lee
Journal:  Int J Mol Sci       Date:  2022-02-07       Impact factor: 5.923

3.  3,4-Dihydroxyphenylethanol and 3,4-dihydroxyphenylacetic acid affect the aggregation process of E46K variant of α-synuclein at different extent: Insights into the interplay between protein dynamics and catechol effect.

Authors:  Benedetta Fongaro; Elia Cappelletto; Alice Sosic; Barbara Spolaore; Patrizia Polverino de Laureto
Journal:  Protein Sci       Date:  2022-07       Impact factor: 6.993

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.